A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:6 - 20
Updated:3/29/2019
Start Date:June 2012
End Date:August 2017

Use our guide to learn which trials are right for you!

A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR

Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with
sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be
studied in these patients. In addition, tumor responses and overall survival will be
assessed.


Inclusion Criteria:

- Histological diagnosis of GIST.

- Patients must have demonstrated either disease progression or intolerance to imatinib
mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain
imatinib in their country

- Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable
disease.

Exclusion Criteria:

- Current treatment with another investigational agent.

- Prior sunitinib treatment.

- Prior therapy with known risk for cardiovascular complications.
We found this trial at
4
sites
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Brno,
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials